Table 1.
Women (n = 21,780) | Men (n = 646,429) | P value | |
---|---|---|---|
Age (yrs) | 59.6 (6.1) | 63.9 (6.1) | < 0.0001 |
A1C (%)† | 7.3 (1.6) | 7.3 (1.4) | < 0.0001 |
BMI (mg/kg2)† | 34.2 (7.2) | 32.6 (6.3) | < 0.0001 |
Mean SBP (mmHg) ‡ | 132 (14) | 132 (14) | 0.27 |
Mean DBP (mmHg) ‡ | 74 (9) | 75 (9) | < 0.0001 |
Mean LDL (mg/dl)‡ | 102 (34) | 89 (29) | < 0.0001 |
Comorbidities (no.)§ | 4.5 (2.2) | 4.3 (2.1) | < 0.0001 |
Non-concordant conditions (no.)║ | 2.7 (1.9) | 2.2 (1.8) | < 0.0001 |
Moderate dose statin use (%) | 29 | 32 | 0.04 |
High dose statin use (%)¶ | 23 | 25 | 0.17 |
Ischemic heart disease (%)§ | 16 | 23 | < 0.0001 |
Care received in community based clinic (%) | 39 | 49 | < 0.0001 |
A1C hemoglobin A1C, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, LDL low-density lipoprotein
*Values are mean (SD) unless otherwise indicated. †Mean value in year prior to study year. ‡Most recent value from year prior to study year. §Comorbidities were identified on the basis of ICD-9 codes listed in the two years prior to the study year. ║Concordant conditions included those whose treatment is generally related to, or overlaps with, diabetes care and include hypertension, hyperlipidemia, obesity, heart failure, ischemic heart disease, peripheral vascular disease, renal disease, and cerebrovascular disease. All others are considered non-concordant. ¶Based on the statin dose at start of study year